Copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Apr 15, 2020; 11(4): 100-114
Published online Apr 15, 2020. doi: 10.4239/wjd.v11.i4.100
Published online Apr 15, 2020. doi: 10.4239/wjd.v11.i4.100
Glargine-300: An updated literature review on randomized controlled trials and real-world studies
Sujoy Ghosh, Department of Endocrinology, IPGME&R, Kolkata 700020, West Bengal, India
Romik Ghosh, Medical Affairs, Sanofi, Mumbai 400072, Maharashtra, India
Author contributions: Both authors contributed to the conception of the paper, literature review, critical revision, and approval of the final version.
Conflict-of-interest statement: Ghosh S has no potential conflict of interest to declare; Ghosh R is an employee of Sanofi, India.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Sujoy Ghosh, MD, Doctor, Department of Endocrinology, IPGME&R, 244, Acharya Jagadish Chandra Bose Road, Bhowanipore, Kolkata 700020, West Bengal, India. drsujoyghosh2000@gmail.com
Received: November 27, 2019
Peer-review started: November 27, 2019
First decision: January 15, 2020
Revised: February 25, 2020
Accepted: March 12, 2020
Article in press: March 12, 2020
Published online: April 15, 2020
Processing time: 130 Days and 18.4 Hours
Peer-review started: November 27, 2019
First decision: January 15, 2020
Revised: February 25, 2020
Accepted: March 12, 2020
Article in press: March 12, 2020
Published online: April 15, 2020
Processing time: 130 Days and 18.4 Hours
Core Tip
Core tip: Despite being a crucial therapeutic option in patients with diabetes, there is a clinical inertia for use of insulin due to fear of hypoglycaemia, weight gain, and complexity of insulin regimens or dosing. Insulin intensification is perceived to be associated with disease worsening, impeding optimal insulin titration and adequate glycaemic control. Insulin glargine 300, the second-generation long-acting insulin analogue, provides an extended and stable action profile, sustained glucose lowering, reduced risk of hypoglycaemia, less weight gain, and flexibility of dosing schedule. This review illustrates the clinical efficiency and safety demonstrated by insulin glargine 300 in randomised clinical trials and real-world studies.